Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to 0.64.

  • Protalix BioTherapeutics' Equity Ratio rose 2206.48% to 0.64 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.64, marking a year-over-year increase of 2206.48%. This contributed to the annual value of 0.59 for FY2024, which is 4803.92% up from last year.
  • As of Q3 2025, Protalix BioTherapeutics' Equity Ratio stood at 0.64, which was up 2206.48% from 0.64 recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Equity Ratio high stood at 0.64 for Q3 2025, and its period low was 0.2 during Q3 2022.
  • In the last 5 years, Protalix BioTherapeutics' Equity Ratio had a median value of 0.31 in 2024 and averaged 0.23.
  • Its Equity Ratio has fluctuated over the past 5 years, first tumbled by 805769.84% in 2022, then surged by 208958.2% in 2024.
  • Over the past 5 years, Protalix BioTherapeutics' Equity Ratio (Quarter) stood at 0.08 in 2021, then tumbled by 132.77% to 0.19 in 2022, then surged by 308.46% to 0.4 in 2023, then surged by 48.04% to 0.59 in 2024, then rose by 9.27% to 0.64 in 2025.
  • Its Equity Ratio was 0.64 in Q3 2025, compared to 0.64 in Q2 2025 and 0.61 in Q1 2025.